Back to Search Results
Back to Results
Melanoma / Skin
General Information
Study Name:
A Phase 2 Study of INCMGA-0012 in Participants with Metastatic Merkel Cell Carcinoma (PODIUM)
Age Group:
Adult
Protocol Number:
NCT03599713
Background Information:
The purpose of this study is to test the safety and effectiveness of the study drug INCMGA00012 in participants with Metastatic Merkel Cell Carcinoma.
Offered at:
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
Eligibility Information
Participants must be 18 years of age or older
Participants must have histologically confirmed MCC with distant metastatic disease as a component of tumor burden and no more than 3 prior systemic treatments, inclusive of systemic adjuvant therapy
Additional eligibility in protocol
Ineligibility Information
Prior programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy
Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders
Additional ineligibility in protocol
Contact Information
Contact Name:
Kelly Jeffords, CCRP
Contact Phone:
571-472-0631
Contact Email:
kelly.jeffords@inova.org
For more information go to:
https://clinicaltrials.gov/ct2/show/NCT03599713?term=03776136&rank=1